{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Dsip",
    "short_name": "DSIP",
    "aliases": [
      "delta-sleep-inducing-peptide",
      "dsip"
    ],
    "classification": {
      "category": "investigational_human",
      "needs_prescription": false,
      "notes": "Classification describes what DSIP is and the general domain where it appears."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-19",
      "human_use_note": "Status reflects how DSIP appears in clinical literature, regulatory contexts, and real-world use. This is descriptive only."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "unknown",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Risk reflects evidence quality, adverse-signal plausibility, and uncertainty. Limited data increases uncertainty.",
      "developmental_systems_of_concern": [
        "cns",
        "neurodevelopment",
        "puberty"
      ],
      "risk_score": 5
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "DSIP is a bioactive compound discussed in research and/or clinical contexts. This entry summarizes what it is, what it is studied for, and what evidence does and does not support, without providing protocols.",
          "evidence_refs": [
            "E1"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "unit": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "min": null,
          "max": null,
          "frequency": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "duration": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": [],
      "current_outlook_bullets": [
        "a bioactive compound discussed in research and/or clinical contexts",
        "this entry summarizes what it is, what it is studied for, and what evidence does and does not support, without providing protocols",
        "sleep quality support",
        "falling asleep more easily (anecdotal)",
        "staying asleep through the night (anecdotal)",
        "circadian rhythm support",
        "next-day recovery and readiness support"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "source_type": "pubmed",
        "source_id": "E1",
        "url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "published_date": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "evidence_grade": "unknown",
        "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-19",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for DSIP",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      }
    ],
    "meta": {},
    "topics": {
      "primary": [
        "topic_sleep_circadian"
      ]
    },
    "slug": "dsip"
  },
  "canonical_name": "Dsip",
  "interactions": {
    "drug_classes": [
      "ssri-snri-serotonergic"
    ],
    "supplement_classes": [],
    "peptides": []
  },
  "practical": {
    "bottom_line": "DSIP is discussed for sleep, but high-quality human evidence is limited. Treat results as uncertain and don't expect consistent outcomes.",
    "benefits": [
      "sleep onset and sleep quality discussions (variable)",
      "stress-related sleep disruption discussions (evidence limited)",
      "often framed as a “sleep peptide” (marketing-heavy ecosystem)"
    ],
    "side_effects_common": [
      "daytime grogginess",
      "vivid dreams",
      "headache"
    ],
    "side_effects_serious": [
      "severe confusion or agitation",
      "fainting or collapse",
      "severe allergic reaction symptoms (hives, facial swelling, trouble breathing)"
    ],
    "who_should_be_cautious": [
      "people with severe insomnia tied to psychiatric or neurologic disease",
      "people taking sedatives, sleep meds, or other CNS-active prescriptions",
      "pregnant or breastfeeding individuals",
      "adolescents (limited evidence and neurodevelopment uncertainty)"
    ],
    "schema_version": "practical_block_v1"
  }
}
